Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Go back to Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults| (NASDAQ: AXSM) | Delayed: 247.85 -2.65 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $250.50 | 52 Week High | $15.74 | |||
| Open | $249.05 | 52 Week Low | $5.37 | |||
| Day High | $253.00 | P/E | N/A | |||
| Day Low | $245.94 | EPS | $0.00 | |||
| Volume | 813,071 | |||||
